Costs of drug treatment in Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
R DodelW Oertel

Abstract

Parkinson's disease (PD) has a major socioeconomic impact on society. The chronic, progressive course of the disease, which often leads to severe disability, results in high expenses for the medical resources used for treatment, care, and rehabilitation of patients as well as reduced or lost productivity as a result of illness or premature death. In Great Britain, it has been estimated that the National Health Service spends up to 383 million pound sterling (1992) annually for the care of PD. This emphasizes the importance of assessing the costs related to this disease. A detailed knowledge of the cost allocation would provide a solid basis on which health care priorities can be rationally set. Next to hospitalization, drug treatment accounts for the highest expense for direct medical costs of PD. Therefore, this analysis focuses on the costs of drug treatment for PD. The cost analysis was based on a retrospective study of 409 patients with PD who were seen over a 1-year period in our movement disorders clinic. The cost of therapy varied considerably depending on the severity of the condition (assessed in the "off" phase), the incidence of motor fluctuations, and the type of PD. In the early stage of the disease (Hoehn and Yahr...Continue Reading

References

Dec 1, 1992·Acta Neurologica Scandinavica·C M ChangK Y Fong
Apr 21, 1990·Lancet·C D Marsden
Nov 1, 1991·Acta Neurologica Scandinavica·J de Pedro-Cuesta, L Stawiarz
May 1, 1990·Southern Medical Journal·L G Miller, J Jankovic
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·W R Gibb, A J Lees
Jul 1, 1987·Annals of Internal Medicine·M DrummondR Cushman
Sep 1, 1987·American Journal of Public Health·J W Hay, R L Ernst
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Feb 1, 1984·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·S Fahn, S B Bressman
Apr 22, 1995·BMJ : British Medical Journal·T Sheldon
Apr 22, 1995·BMJ : British Medical Journal·R Watson
Mar 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·W H Oertel, R C Dodel
Jan 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·S T GancherW R Woodward
Mar 4, 1995·BMJ : British Medical Journal·N Quinn
Jun 1, 1994·Australian and New Zealand Journal of Medicine·J A SavigeJ C Duggan
May 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·G K WenningN P Quinn
Aug 1, 1994·American Journal of Public Health·R L Ernst, J W Hay
Apr 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·P D Swanson
Sep 11, 1993·BMJ : British Medical Journal·R Robinson
Apr 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J HughesG M Stern
Jan 11, 1996·The New England Journal of Medicine·D A BennettD A Evans
Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·E TandbergJ A Aarli
Jan 9, 1992·PharmacoEconomics·S E Parker, P G Davey
Jun 7, 1992·PharmacoEconomics·P J Davey, S R Leeder
Dec 9, 1995·PharmacoEconomics·M Malek
Jan 1, 1992·Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology·M NakataB Jonsson

❮ Previous
Next ❯

Citations

Sep 24, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·J L MontastrucJ M Senard
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·A D SiderowfM B Stern
Jun 7, 2005·Neurotoxicology·Bernard Weiss
Jul 27, 2001·Parkinsonism & Related Disorders·M SchenkmanK Whetten-Goldstein
Feb 8, 2003·Parkinsonism & Related Disorders·T KeränenA Takala
Oct 19, 2012·The New England Journal of Medicine·Michael S Okun
Dec 6, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M PéchevisUNKNOWN Trial Study Group
Dec 2, 2008·Neuropsychiatric Disease and Treatment·Ozlem GuneyselOzge Onur
Jul 27, 2002·PharmacoEconomics·Cynthia S PalmerEdward H Snyder
Jan 18, 2011·Journal of Medical Economics·Leslie J FindleyMathias Schifflers
Oct 28, 2008·Disability and Rehabilitation·Antonio P VargasMiriam Melo
Mar 8, 2008·Expert Opinion on Drug Safety·Ubaldo Bonuccelli, Roberto Ceravolo
May 5, 2001·Expert Opinion on Pharmacotherapy·T Müller
Jun 27, 2006·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Dennis John CordatoLitsa Morfis
Aug 6, 2004·Clinical Rehabilitation·Heather Gage, Lesley Storey
May 10, 2002·Pharmacoepidemiology and Drug Safety·Olivia LeoniGianmario Frigo
Jan 13, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Davide FerrazzoliGiuseppe Frazzitta
Feb 26, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Stacey L KowalAnjali Jain
Mar 18, 2006·Acta Neurologica Scandinavica·C VossiusJ P Larsen
Jun 1, 2019·Expert Opinion on Pharmacotherapy·Alexander S Wang, Steven A Gunzler
Oct 12, 2013·Journal of Applied Behavior Analysis·Keith D Allen, Dustin P Wallace
Mar 7, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Mark GuttmanC David Naylor
Aug 29, 2006·Medical & Biological Engineering & Computing·Eduardo Rocon de LimaSlawomir J Nasuto
Dec 23, 2017·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Caroline C RealErik Fj de Vries
Sep 28, 2017·Parkinson's Disease·Gerson Suarez-CedenoMya C Schiess
Aug 29, 2021·Pharmaceuticals·E Maruthi Prasad, Shih-Ya Hung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
A E EliaA Albanese
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
P LindgrenR Dodel
© 2022 Meta ULC. All rights reserved